Is het Asensus Surgical dividend veilig?
Asensus Surgical verhoogt het dividend al 0 jaar.
Binnen de laatste 10 jaar heeft Asensus Surgical deze met jaarlijks 0 % verlaagd verhoogd.
Op 5-jaarsbasis is de uitkering met daalde toegenomen met 0 %.
De analisten verwachten voor het lopende boekjaar een Dividendverlaging van -100,000%.
Asensus Surgical Aktienanalyse
Wat doet Asensus Surgical?
Asensus Surgical Inc is a medical technology company based in Research Triangle Park, North Carolina, USA. It was founded in 1995 by Joe Mussallem, who still serves as President and CEO today. Formerly known as "TransEnterix," the company changed its name to Asensus Surgical Inc in 2021 to reflect its commitment to advanced, data-driven surgery.
Asensus Surgical Inc aims to revolutionize the way surgical procedures are performed by utilizing robotic technology and offering a wide range of products and services.
The company's business model is based on transferring skills typically held by surgeons to robots, with a focus on precision in surgeries. Through the use of machine learning and computer vision, Asensus Surgical Inc allows surgeons to monitor their own movements in real-time on robotic arms in the operating room, leading to significantly more precise work.
The company's main division is the Senhance® Surgical System platform. The system consists of three components: the artificial intelligence technology of the Intelligent Surgical Units (ISU), touchscreen consoles, and a further sterilization cabinet.
During surgical procedures, the Intelligent Surgical Units process real-time data, enabling improved decision-making during the operation. The touchscreen consoles serve as the user interface, allowing surgeons to monitor and control the operation in real-time on a screen. The sterilization cabinet ensures that the system is sterilized between procedures.
In addition to the Senhance® Surgical System platform, Asensus Surgical Inc also offers other innovative products such as disposable instruments. This includes "3-mm instruments," special miniature instruments that can be used through very small incisions in the patient's body. These minimize scarring and enable faster recovery.
Another product offered by Asensus Surgical Inc is the AI Camera Assistant, which is based on artificial intelligence (AI). This is a computer software that supports surgeons by analyzing real-time images and enabling monitoring and analysis during the procedure. Combined with the Senhance® Surgical System, the AI Camera Assistant allows for more precise and safer work.
Asensus Surgical Inc has achieved several significant milestones in its history. One of these milestones is the FDA approval of the Senhance® Surgical System platform in 2017. Furthermore, in 2020, the company entered into an agreement with Johnson & Johnson to advance the marketing of products.
Overall, Asensus Surgical Inc is an emerging company in the highly innovative field of robotics in surgery. With its advanced products and focus on precise, safe, and straightforward surgery, the company will continue to play an important role in the healthcare industry, saving and improving lives. Asensus Surgical is een van de populairste bedrijven op Eulerpool.com.Aandelen spaarplannen bieden een aantrekkelijke mogelijkheid voor beleggers om op de lange termijn vermogen op te bouwen. Een van de belangrijkste voordelen is het zogenaamde cost-average-effect: door regelmatig een vast bedrag in aandelen of aandelenfondsen te investeren, koopt men automatisch meer aandelen wanneer de prijzen laag zijn, en minder wanneer ze hoog zijn. Dit kan leiden tot een voordeligere gemiddelde prijs per aandeel over de tijd. Bovendien maken aandelen spaarplannen het ook voor kleine beleggers mogelijk om toegang te krijgen tot dure aandelen, aangezien ze al met kleine bedragen kunnen deelnemen. De regelmatige investering bevordert ook een gedisciplineerde beleggingsstrategie en helpt emotionele beslissingen, zoals impulsief kopen of verkopen, te voorkomen. Daarnaast profiteren beleggers van de potentiële waardestijging van de aandelen en van dividenduitkeringen die herinvesteerd kunnen worden, wat het effect van samengestelde interest versterkt en daarmee de groei van het geïnvesteerde kapitaal.